LeMaitre Guides Q3 Gross Margin to 72.2%, PMDA Backs AV Indication Without Trials
LMAT is trading near its 52-week low of $78.65 (3.6% above the low).
Summary
LeMaitre Vascular guided Q3 gross margin to 72.2%, building on Q2's 72.1% and signaling continued operational leverage. The company also received informal PMDA support for an AV indication by 2029–30 without requiring additional trials, a significant regulatory de-risking event. A Canada Artegraft launch is set for September, with longer grafts and packaging improvements targeted for H2 2027. These catalysts come as the stock trades near its 52-week low, potentially refocusing investors on the growth pipeline.
At the time of this announcement, LMAT was trading at $81.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $78.65 to $118.01. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.